Adverse Drug Reaction Classification System

         

Pharmaceutical Information
Drug Name Fluticasone furoate
Drug ID BADD_D00946
Description Fluticasone furoate is a synthetic glucocorticoid available as an inhaler and nasal spray for various inflammatory indications[FDA Label][F4364]. Fluticasone furoate was first approved in 2007[L5965].
Indications and Usage Fluticasone furoate is indicated as an inhaler for the treatment and management of asthma by prophylaxis[FDA Label][F4364]. The fluticasone furoate nasal spray is indicated for treating season and perennial allergic rhinitis[FDA Label][A177130].
Marketing Status approved
ATC Code R01AD12; R03BA09
DrugBank ID DB08906
KEGG ID D06315
MeSH ID C523187
PubChem ID 9854489
TTD Drug ID D0Y7JU
NDC Product Code 47848-057; 64918-1915; 0135-0615; 64918-1910; 64918-1916; 22552-0042; 63379-083; 55018-302; 58175-0553; 0135-0616; 63592-3370; 0173-0874; 0173-0888; 50090-5967; 49076-6452; 59057-010; 0173-0876; 50090-6075; 15308-2021; 52482-008; 63379-084; 49076-6451; 59057-009; 64918-1117
UNII JS86977WNV
Synonyms fluticasone furoate
Chemical Information
Molecular Formula C27H29F3O6S
CAS Registry Number 397864-44-7
SMILES CC1CC2C3CC(C4=CC(=O)C=CC4(C3(C(CC2(C1(C(=O)SCF)OC(=O)C5=CC=CO5)C)O)F)C)F
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Throat irritation07.05.05.037; 22.12.03.029---
Thrombosis24.01.01.006---
Tongue coated07.14.02.011---
Toothache07.09.06.001--
Tremor17.01.06.002--
Ulcer08.03.06.001---
Urinary retention20.02.02.011--
Urticaria10.01.06.001; 23.04.02.0010.001345%
Visual acuity reduced06.02.10.012; 17.17.01.0110.000611%
Visual impairment06.02.10.013---
Vomiting07.01.07.0030.000611%
Vulvovaginal candidiasis11.03.03.005; 21.14.02.003---
Wheezing22.03.01.0090.002262%
Intervertebral disc protrusion15.10.01.004---
Rhinalgia22.12.03.020---
Respiratory tract congestion22.02.07.003---
Nasal discomfort22.12.03.012---
Secretion discharge08.01.03.019---
Growth retardation05.03.02.007; 14.03.02.031; 15.03.05.0160.000917%
Haemorrhage24.07.01.0020.000917%-
Pulmonary mass22.02.07.004---
Lung neoplasm malignant16.19.02.001; 22.08.01.001---
Cardiac disorder02.11.01.003---
Connective tissue disorder10.04.04.026; 15.06.01.006---
Mediastinal disorder22.09.03.001---
Ill-defined disorder08.01.03.049---
Adverse drug reaction08.06.01.009---
Disease recurrence08.01.03.050---
Obstructive airways disorder22.03.01.011---
Sinus disorder22.04.06.002--
The 5th Page    First    Pre   5 6    Next   Last    Total 6 Pages